News Release

New drug could help those with CAH reduce the use of corticosteroids

Peer-Reviewed Publication

Michigan Medicine - University of Michigan

People born with the common form of congenital adrenal hyperplasia lack an enzyme in the adrenal glands needed to make the hormones cortisol and aldorsterone, which are involved in the body’s response to stress and blood pressure regulation.  

The adrenals of children with this rare condition reroute hormone production to excess androgens, which tend to make them mature early and suffer from short stature and infertility as adults.

To make matters worse, a routine stomach virus can send CAH patients into what is known as an adrenal crisis, causing shock if not treated immediately. 

The go-to therapy for children and adults with CAH are high dose corticosteroids, which come with a host of side effects, including weight gain, diabetes, osteoporosis and cognitive dysfunction.  

A study, led by Richard Auchus, M.D., Ph.D., of the U-M Medical School Department of Pharmacology and internal medicine and investigators from the CAHtalyst Adult Trial provides strong evidence for an effective compound, crinecerfont, that could allow people with CAH to reduce their dose of replacement corticosteroids.  

Published in the New England Journal of Medicine, the study randomized adults with CAH to take crinecerfont or a placebo along with their normal corticosteroid regimen. 

A parallel study was conducted in children with CAH, and a companion paper reported these results.  

After a month, patients on the drug, but not placebo, had a reduction in the adrenal androgen, androstenedione, by half.

For the second part of the study, each group had their dose of glucocorticoid gradually reduced. 

The group on crinecerfont was able to maintain a reduction in the adrenal hormone after 24 weeks with a glucocorticoid dose close to that naturally produced by the body. 

“These patients are still cortisol deficient and thus will still need cortisol replacement, but with crinecerfont, they need much less and could be less likely to experience the longterm negative effects of current glucocorticoid dosing,” said Auchus. 

Additional investigators and authors include Kyriakie Sarafoglou, M.D., Mimi S. Kim, M.D., Maya Lodish, M.D., Eric I. Felner, M.D., Laetitia Martinerie, M.D., Ph.D., Natalie J. Nokoff, M.D., María Clemente, M.D., Ph.D., Patricia Y. Fechner, M.D., Maria G. Vogiatzi, M.D., Phyllis W. Speiser, M.D., Gelliza B.G. Rosales, M.P.H., Eiry Roberts, M.D., George S. Jeha, M.D., Robert H. Farber, Ph.D., and Jean L. Chan, M.D., Oksana Hamidi, D.O., Rosario Pivonello, M.D., Ph.D., Irina Bancos, M.D., Gianni Russo, M.D., Selma F. Witchel, M.D., Andrea M. Isidori, M.D., Ph.D., Patrice Rodien, M.D., Ph.D., Umasuthan Srirangalingam, Ph.D., Florian W. Kiefer, M.D., Ph.D., Henrik Falhammar, M.D., Ph.D., Deborah P. Merke, M.D.,Nicole Reisch, M.D., Gordon B. Cutler, Jr., M.D., Julia Sturgeon, M.S., Vivian H. Lin, M.D., Xin He, M.D. and Ming Chen, M.D. Ph.D. 

Auchus reports consulting fees from Neurocrine Biosciences, Crinetics Pharmaceuticals, Diurnal LTD, H Lundbeck A/S, and Novo Nordisk and contracted research support from Neurocrine Biosciences, Crinetics Pharmaceuticals, Diurnal LTD, and Spruce Biosciences. 

Papers cited:

“Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia,” New England Journal of Medicine. DOI: 10.1056/NEJMoa2404656 

“Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia,” New England Journal of Medicine. DOI: 10.1056/NEJMoa2404655 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.